Universal Biosensors Signs Vendor Agreement with Chewy, Launches on Amazon
Universal Biosensors has secured a Vendor Master Purchase Agreement with Chewy and launched its Petrackr veterinary glucose monitoring system on Amazon, positioning itself for significant growth in North America's online pet care market.
- Signed Vendor Master Purchase Agreement with Chewy, a leading US pet retailer
- Launched Petrackr product on Amazon platform
- Nine months of ecommerce development preceding agreements
- Agreements are ongoing but terminable with 30 days’ notice
- Expect material sales impact from expanded online distribution
Universal Biosensors Enters Major US Retail Channels
Universal Biosensors, Inc. (ASX: UBI) has taken a decisive step to broaden the market presence of its veterinary blood glucose monitoring system, Petrackr, by signing a Vendor Master Purchase Agreement with Chewy, Inc., one of the largest pet retailers in the United States. Complementing this, UBI has also launched Petrackr on Amazon, tapping into the largest online marketplace for veterinary products in North America.
Chewy, which generated over USD $11 billion in revenue in 2023 and serves more than 20 million active customers, represents a significant channel for Universal Biosensors to reach pet owners directly. The agreement follows nearly a year of collaboration and ecommerce capability development, underscoring UBI’s strategic commitment to online retail as the primary sales avenue for veterinary blood glucose monitoring systems.
Strategic Shift to Online Sales
John Sharman, Managing Director of Universal Biosensors, highlighted the shift in sales dynamics: "While our initial focus was on professional veterinary networks, it has become clear that the majority of sales occur online. Chewy and Amazon collectively dominate this space, and we expect these agreements to materially boost Petrackr sales moving forward." This pivot reflects broader trends in pet healthcare, where convenience and digital engagement increasingly influence purchasing decisions.
The Petrackr system, designed specifically for cats and dogs, integrates a Bluetooth-enabled analyzer with a mobile app, allowing pet owners to monitor and share their pets’ blood glucose data seamlessly with veterinarians. This tech-forward approach aligns well with the digital-first platforms of Chewy and Amazon, potentially accelerating adoption among tech-savvy pet parents.
Terms and Market Implications
Notably, the agreements with Chewy and Amazon are ongoing but include a 30-day termination clause by either party, introducing a degree of uncertainty around long-term stability. However, the groundwork laid over the past nine months suggests a solid foundation for sustained collaboration.
For investors, these developments signal a critical inflection point for Universal Biosensors. The company’s ability to leverage these powerful ecommerce platforms could unlock significant revenue growth and enhance brand visibility in a competitive veterinary products market.
Looking ahead, monitoring sales performance through these channels and the competitive response will be key to assessing the full impact of this strategic expansion.
Bottom Line?
Universal Biosensors’ ecommerce push via Chewy and Amazon could redefine its growth trajectory in veterinary care.
Questions in the middle?
- How quickly will Petrackr sales ramp up on Chewy and Amazon platforms?
- What competitive responses might emerge from other veterinary glucose monitoring providers?
- Will the 30-day termination clause affect long-term partnership stability?
